The latest market price of axitinib/axitinib in 2025
Axitinib/Axitinib is a kinase inhibitor that mainly blocks the activity of an abnormal protein that releases a reproduction signal to cancer cells, thereby slowing or preventing the spread of cancer cells. The drug is particularly useful in advanced renal cell carcinoma (RCC), a cancer that starts in the cells of the kidneys, especially when other treatments haven't worked. Axitinib can be used alone or in combination with avelumab or pembrolizumab for the treatment of advanced renal cell carcinoma.
Axitinib is an oral tablet that is usually recommended to be taken twice daily, before or after a meal. Patients should try to take it at the same time every day, approximately 12 hours apart. It is important to strictly follow your doctor's instructions and do not take more or less than the prescribed frequency. Patients need to swallow the tablets whole with a glass of water and do not cut, chew or crush them. If vomiting occurs after taking the medication, the patient should not take additional doses but should continue with their regular dosing schedule. Doctors may gradually adjust the dose of axitinib based on patient response and side effects, no more than once every two weeks.

The original drug of axitinib has been launched in China and has been included in the reimbursement scope of Class B medical insurance. Common specifications include1mg 14 tablets and 5mg 28 tablets, etc. The market price is generally more than 2,000 RMB. At the same time, the price of axitinib’s original drug in overseas markets may reach about 6,000 yuan.
In addition, there are a variety of generic drugs of axitinib on the overseas market. The drug ingredients are consistent with the original drug, including the Laos version, the Indian version and the Bangladeshi version. The selling price of these generic drugs is usually around 1,000 yuan, but due to exchange rate fluctuations, the specific price may change.
Reference materials:https://medlineplus.gov/druginfo/meds/a612017.html
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)